tirzepatide and hormone balance Testosterone Testosterone, Estrogen & Weight Loss:

Participants A total of 1545 participants (82% of all participants treated with tirzepatide in SURMOUNT1) met criteria and were included in the present analyses, with 278 (18.0%) categorized as late responders and 1267 (82.0%) categorized as early responders

At higher doses, monitoring becomes more important

If you notice that early dosing, which was previously well-tolerated, starts producing nausea after significant weight loss, the changing pharmacokinetics of your lighter body may be the explanation

Always ensure that your compounded tirzepatide is sourced from a state-licensed or FDA-registered compounding facility to reduce the risk of receiving a substandard or unsafe medication